Market research
4527.TSE Rohto Pharmaceutical Co.,Ltd
TSE JPY Consumer Defensive
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 607B
- P/E ratio
- 19.18
- Analyst target
- 3290
- Dividend yield
- 1.7%
- Beta
- -0.41
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- ISIN
- JP3982400008
- Market cap
- 607B
- P/E ratio
- 19.18
- Analyst target
- 3290
- Dividend yield
- 1.7%
- Beta
- -0.41
About
About Rohto Pharmaceutical Co.,Ltd
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods Japan, China, and internationally. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin, lip balms, sunscreens, functional cosmetics, etc.; medicine for internal use, such as digestive and herbal medicines; regenerative medicines; OTC pharmaceutical products, including ophthalmic, dermatological, gastrointestinal, and diagnostic drugs, as well as Chinese herbal medicines, and supplements. In addition, the company operates beauty counters that provide beauty and health services; and manufactures and sells diagnostic reagents, as well as provides investment management services; and contract development and manufacturing services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. The company was founded in 1899 and is headquartered in Osaka, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4527.TSE discussion.
5 years, 6 months ago
Rohto Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.
From a valuation standpoint, the stock is 80.9% more expensive than other stocks from the Consumer Defensive sector with a price to sales ratio of 1.9.
Rohto Pharmaceutical Co., Ltd's total revenue sank by 2.1% to $47B since the same quarter in the previous year.
Its net income has dropped by 6.7% to $5B since the same quarter in the previous year.
Based on the above factors, Rohto Pharmaceutical Co., Ltd gets an overall score of 0/5.